NOS3 and pulmonary fibrosis: Taken together, the deterioration of pulmonary fibrosis in the BLM-treated n/i/eNOS−/− mice observed in this study may be explained by the above mechanism, although further studies are needed to clarify the mechanisms underlying the antifibrotic activity of NO in the setting of fibrotic lung diseases.